Who
Janet M.J. Hammond
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Atea Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $54K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Jan 2021
- Last trade
- 31 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —58,050 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $60K14,136 at $4.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,800 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,800 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,000 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,000 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —58,050 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $60K14,136 at $4.24 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,800 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,250 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —46,800 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —11,250 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $43K14,134 at $3.06 | filing |
| 1 Feb 2024filed 2 Feb 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $54K14,029 at $3.84 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,800 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,200 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —46,800 | filing |
News
No headline names them, or the companies they trade most, lately.